Deprecated function: Return type of DatabaseStatementBase::execute($args = [], $options = []) should either be compatible with PDOStatement::execute(?array $params = null): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2246 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
Deprecated function: Return type of DatabaseStatementEmpty::current() should either be compatible with Iterator::current(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
Deprecated function: Return type of DatabaseStatementEmpty::next() should either be compatible with Iterator::next(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
Deprecated function: Return type of DatabaseStatementEmpty::key() should either be compatible with Iterator::key(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
Deprecated function: Return type of DatabaseStatementEmpty::valid() should either be compatible with Iterator::valid(): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
Deprecated function: Return type of DatabaseStatementEmpty::rewind() should either be compatible with Iterator::rewind(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
Original Research
Imiquimod Cream 2.5% and 3.75% Applied Once Daily to Treat External Genital Warts in Men
Dr. Rosen is from the Department of Dermatology, Baylor College of Medicine, Houston, Texas. Dr. Nelson is from the Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, California. Dr. Ault is from the Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia.
The clinical studies reported in this article were sponsored and funded by Valeant Pharmaceuticals International, Inc. Dr. Rosen has served on the advisory board for and has received honoraria from Valeant Pharmaceuticals North America, LLC. Drs. Nelson and Ault have been advisors for Valeant Pharmaceuticals North America, LLC. Dr. Nelson also has received honoraria and is a consultant and speaker for Actavis and Bayer Health Care Pharmaceuticals; has received research grants from Agile Therapeutics and Bayer Health Care Pharmaceuticals; and is a consultant for Agile Therapeutics, ContraMed LLC, Merck & Co, Microchips Biotech, PharmaNest, and Teva Pharmaceutical Industries Ltd. She also is a speaker for Merck & Co; Pfizer, Inc; and Teva Pharmaceutical Industries Ltd.
Correspondence: Ted Rosen, MD, Department of Dermatology, Baylor College of Medicine, 1977 Butler Blvd, Houston, TX 77030 (vampireted@aol.com).
Acknowledgments—The authors thank Christina Cognata Smith, PharmD, and Mandeep Kaur, MD (both previously of Valeant Pharmaceuticals North America, LLC, Bridgewater, New Jersey), as well as Brian Bulley, MSc (Inergy Limited, Lindfield, West Sussex, United Kingdom), for assistance with the preparation of the manuscript. Valeant Pharmaceuticals North America, LLC, funded Inergy’s activities pertaining to this analysis.
